Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug373 | Association atezolizumab + BDB001 + RT Wiki | 0.35 |
Navigate: Correlations HPO
There are 2 clinical trials
Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
Description: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with pancreatic cancer. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with virus associated tumors. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with non-small cell lung cancer. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of 6-month progression-free rat (PFR) and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed at 6 months following treatment onset and more than 24 weeks, based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with soft-tissue sarcoma. Time: 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with bladder cancer. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with triple negative breast cancer. Time: Within 6 months of treatment onsetDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with pancreatic cancer. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with virus-associated tumor. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with non-small cell lung cancer. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with bladder cancer. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with triple negative breast cancer. Time: 6 monthsDescription: Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed at 6 months, based on RECIST 1.1 criteria.
Measure: 6-month objective response rate (ORR) independently for each population. Time: 6 monthsDescription: Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed within 24 wekks after treatment onset, based on RECIST 1.1 criteria.
Measure: Objective response rate (ORR) within 24 weeks of treatment onset, independently for each population. Time: Within 6 monthsDescription: Best overall response is defined as the best response across all time points (RECIST 1.1). The best overall response is determined once all the data for the patient is known (RECIST 1.1).
Measure: Best overall response, independently for each population. Time: Throughout the treatment period, an expected average of 6 monthsDescription: Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first.
Measure: 1-year progression-free survival, independently for each population. Time: 1 yearDescription: Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first.
Measure: 2-year progression-free survival, independently for each population. Time: 2 yearsDescription: Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause).
Measure: 1-year overall survival, independently for each population. Time: 1 yearDescription: Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause).
Measure: 2-year overall survival, independently for each population. Time: 2 yearsDescription: Toxicity graded using the Common Terminology Criteria for Adverse Events version 5.
Measure: Safety profile, independently for each population: Common Terminology Criteria for Adverse Events version 5 Time: Throughout the treatment period, an expected average of 6 monthsDescription: Levels of immune cells in tumor will be measured by immunohistochemistry.
Measure: Tumor immune cells levels Time: before treatment onset and cycle 3 day 1 (each cycle is 21 days)Description: Levels of cytokines in blood will be measured by ELISA.
Measure: Blood cytokines levels Time: baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)Description: Levels of lymphocytes in blood will be measured by flow cytometry.
Measure: Blood lymphocytes levels Time: baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)Description: Levels of kynurenine in blood will be measured by ELISA.
Measure: Blood kynurenine levels Time: baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
Description: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with pancreatic cancer. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with virus associated tumors. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with non-small cell lung cancer. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of 6-month progression-free rat (PFR) and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed at 6 months following treatment onset and more than 24 weeks, based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with soft-tissue sarcoma. Time: 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with bladder cancer. Time: Within 6 months of treatment onsetDescription: Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.
Measure: Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with triple negative breast cancer. Time: Within 6 months of treatment onsetDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with pancreatic cancer. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with virus-associated tumor. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with non-small cell lung cancer. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with bladder cancer. Time: 6 monthsDescription: Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.
Measure: 6-month Progression-free rate (PFR) in patients with triple negative breast cancer. Time: 6 monthsDescription: Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed at 6 months, based on RECIST 1.1 criteria.
Measure: 6-month objective response rate (ORR) independently for each population. Time: 6 monthsDescription: Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed within 24 wekks after treatment onset, based on RECIST 1.1 criteria.
Measure: Objective response rate (ORR) within 24 weeks of treatment onset, independently for each population. Time: Within 6 monthsDescription: Best overall response is defined as the best response across all time points (RECIST 1.1). The best overall response is determined once all the data for the patient is known (RECIST 1.1).
Measure: Best overall response, independently for each population. Time: Throughout the treatment period, an expected average of 6 monthsDescription: Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first.
Measure: 1-year progression-free survival, independently for each population. Time: 1 yearDescription: Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first.
Measure: 2-year progression-free survival, independently for each population. Time: 2 yearsDescription: Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause).
Measure: 1-year overall survival, independently for each population. Time: 1 yearDescription: Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause).
Measure: 2-year overall survival, independently for each population. Time: 2 yearsDescription: Toxicity graded using the Common Terminology Criteria for Adverse Events version 5.
Measure: Safety profile, independently for each population: Common Terminology Criteria for Adverse Events version 5 Time: Throughout the treatment period, an expected average of 6 monthsDescription: Levels of immune cells in tumor will be measured by immunohistochemistry.
Measure: Tumor immune cells levels Time: before treatment onset and cycle 3 day 1 (each cycle is 21 days)Description: Levels of cytokines in blood will be measured by ELISA.
Measure: Blood cytokines levels Time: baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)Description: Levels of lymphocytes in blood will be measured by flow cytometry.
Measure: Blood lymphocytes levels Time: baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)Description: Levels of kynurenine in blood will be measured by ELISA.
Measure: Blood kynurenine levels Time: baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports